Clinical Trial: D9077C00001

Trial Status: Open
Disease Type: Lung
Trial ID D9077C00001

A Phase 2 Open-Label, Multicenter Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-Stage (II-IIIA) NSCLC

5 Locations


Arlington Office

Alexandria Office

Fairfax Office

Loudoun Office

Gainesville Office

Learn More About This Trial

Other Relevant Trials
Trial ID NAV-1104
Sponsor ID Navire Pharma

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

1 Location
Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

1 Location